Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors
| Autor: | Nicola Mozzillo, Federica Marenco, Paolo Curatolo, A. De Paoli, Luca Giovanni Campana, Lorenzo Borgognoni, P.A. Ascierto, Stefania Bucher, Michele Guida, Alessandro Testori, Simone Mocellin, Carlo Riccardo Rossi, Roberta Rotunno, Antonio Bonadies, Pietro Quaglino, Massimo Framarini, G.L. De Salvo |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Oncology Electrochemotherapy Skin Neoplasms Kaplan-Meier Estimate Injections Intralesional 030207 dermatology & venereal diseases Breast cancer 0302 clinical medicine Squamous cell carcinoma Medicine Prospective Studies Prospective cohort study Melanoma Aged 80 and over Sarcoma General Medicine Middle Aged Cutaneous metastases Basal cell carcinoma Treatment Outcome 030220 oncology & carcinogenesis Carcinoma Squamous Cell Female Breast carcinoma Adult medicine.medical_specialty Antineoplastic Agents Breast Neoplasms Bleomycin Young Adult 03 medical and health sciences Internal medicine Carcinoma Humans Sarcoma Kaposi Aged Proportional Hazards Models business.industry medicine.disease Carcinoma Basal Cell Surgery Cisplatin business |
| Zdroj: | European Journal of Surgical Oncology (EJSO). 42:1914-1923 |
| ISSN: | 0748-7983 |
| DOI: | 10.1016/j.ejso.2016.06.399 |
| Popis: | BackgroundCutaneous metastases represent a therapeutic challenge. An increasing body of experience suggests that electrochemotherapy (ECT) provides effective tumor control, although its evidence basis should be strengthened.MethodsThis prospective, multicenter, observational study enrolled patients with superficial metastases, who underwent ECT at 10 centers between 2008 and 2013. Outcomes included adherence to European Standard Operating Procedures of ECT (ESOPE), tumor response, local progression-free survival (LPFS), toxicity and patient-reported outcomes (PROs, EORTC QLQ-C30 plus an 8-item questionnaire).ResultsWe enrolled 376 eligible patients. Tumor histotype distribution was as follows: melanoma, 56%; squamous cell carcinoma, 11%; Kaposi sarcoma, 11%; breast carcinoma, 8%; basal cell carcinoma, 6%; soft tissue sarcomas, 3%; others, 5%. We registered 1304 target tumors (median size 1 cm). Treatment adhered to ESOPE in 88% of patients as to the route of drug administration, and in 70% as to electrode application. The procedure was mainly performed under sedation (64.6%) and by using intravenous chemotherapy (93.4%). Tumor response rate at 60 days was 88% (complete, 50%). Small tumor size predicted complete response achievement (OR 2.24, p = 0.003), higher LPFS (HR 0.68, p = 0.004) and improved PROs (Global Health Status, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect